Mr. Rose is a practicing Registered Pharmacist and has led his own consulting group, Rose and Company, since 2009. Mr. Rose has held positions of increasing responsibility in Sales, Marketing and Administration with Eli Lilly and Company, Glaxo Inc, (now GSK) (Vice President, Hospital Sales), ICN Pharmaceuticals (now Bausch Health) (Vice President and General Manager, North America) and Obagi Medical Products (President and CEO).
Mr. Rose specializes in market analysis, market preparation and full strategy development to maximize commercial potential. This includes developing KOL and Advocacy Group support, pharmacoeconomic data generation, 3rd Party payer strategy development, marketing and sales planning, e-commerce, conventional and emerging distribution opportunities, packaging, and pricing strategy development. Mr. Rose has consulted on multiple commercial development projects with companies including Alza (now J&J), Reliant Pharmaceuticals (now GSK) and Peplin Inc. (now LEO).
Mr. Rose is a graduate of Union University, Albany College of Pharmacy and Health Sciences, Albany, New York.
Prior to assuming the role of CCO, Mr. Rose had been a consultant for Hexima since 1 September, 2020.
Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains its OVERWEIGHT rating and a $0.75 12-month price target. View the full report (pdf)
Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 29 April 2022 at 12:30pm AEST. Mr Aldridge provided a company overview and discussed its phase II clinical trial, including when the company is expecting results from the trial. This...
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 March 2022. Achievements for the quarter include: Appointed Mr Philip Rose as Chief Commercial Officer and strengthened the manufacturing team with the appointment of Mr Om...